{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:10:18Z","timestamp":1760911818106,"version":"build-2065373602"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.phrs.2019.03.004","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T17:27:33Z","timestamp":1551720453000},"page":"27-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Anti-arrhythmic therapy in patients with non-ischemic cardiomyopathy"],"prefix":"10.1016","volume":"143","author":[{"given":"Riccardo","family":"Proietti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"AlTurki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.phrs.2019.03.004_bib0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jchf.2016.09.017","article-title":"Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis","volume":"5","author":"Di Marco","year":"2017","journal-title":"JACC Heart Fail."},{"issue":"6","key":"10.1016\/j.phrs.2019.03.004_bib0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.joa.2013.12.008","article-title":"Cardiac fibrosis as a determinant of ventricular tachyarrhythmias","volume":"30","author":"Morita","year":"2014","journal-title":"J. Arrhythm."},{"issue":"22","key":"10.1016\/j.phrs.2019.03.004_bib0015","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/eurheartj\/ehx028","article-title":"Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials","volume":"38","author":"Francis","year":"2017","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.phrs.2019.03.004_bib0020","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1113\/JP270534","article-title":"Therapy for ventricular arrhythmias in structural heart disease: a multifaceted challenge","volume":"594","author":"Proietti","year":"2016","journal-title":"J. Physiol."},{"issue":"10","key":"10.1016\/j.phrs.2019.03.004_bib0025","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.hrthm.2016.07.001","article-title":"Long-term outcomes after catheter ablation of ventricular tachycardia in patients with and without structural heart disease","volume":"13","author":"Kumar","year":"2016","journal-title":"Heart Rhythm"},{"issue":"8","key":"10.1016\/j.phrs.2019.03.004_bib0030","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.tcm.2017.06.003","article-title":"Arrhythmic risk stratification in non-ischemic dilated cardiomyopathy: where do we stand after DANISH?","volume":"27","author":"Dilaveris","year":"2017","journal-title":"Trends Cardiovasc. Med."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.004_bib0035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00129784-200101020-00004","article-title":"Mechanisms underlying ventricular arrhythmias in idiopathic dilated cardiomyopathy","volume":"1","author":"Merino","year":"2001","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"22","key":"10.1016\/j.phrs.2019.03.004_bib0040","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/01.CIR.98.22.2404","article-title":"Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy","volume":"98","author":"Pogwizd","year":"1998","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.phrs.2019.03.004_bib0045","first-page":"3893","article-title":"Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice","volume":"118","author":"Baudenbacher","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.004_bib0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/cvr\/cvv023","article-title":"Targets for therapy in sarcomeric cardiomyopathies","volume":"105","author":"Tardiff","year":"2015","journal-title":"Cardiovasc. Res."},{"issue":"7","key":"10.1016\/j.phrs.2019.03.004_bib0055","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.004_bib0060","first-page":"587","article-title":"Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR","volume":"6","author":"Moravsky","year":"2013","journal-title":"JACC: Cardiovasc. Imaging"},{"issue":"11","key":"10.1016\/j.phrs.2019.03.004_bib0065","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jacc.2010.05.010","article-title":"Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy","volume":"56","author":"O\u2019Hanlon","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.004_bib0070","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2004.11.043","article-title":"Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy","volume":"45","author":"Adabag","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.004_bib0075","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0735-1097(03)00827-1","article-title":"Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy. an independent marker of sudden death risk in young patients","volume":"42","author":"Monserrat","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"39","key":"10.1016\/j.phrs.2019.03.004_bib0080","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"members","year":"2014","journal-title":"Eur. Heart J."},{"issue":"39","key":"10.1016\/j.phrs.2019.03.004_bib0085","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Authors\/Task Force m","year":"2014","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.phrs.2019.03.004_bib0090","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo","volume":"324","author":"Echt","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.phrs.2019.03.004_bib0095","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ejhf.541","article-title":"Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives","volume":"18","author":"Ammirati","year":"2016","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.004_bib0100","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijcard.2006.04.080","article-title":"Beta-blocker therapy for dynamic left ventricular outflow tract obstruction induced by exercise","volume":"117","author":"Cabrera-Bueno","year":"2007","journal-title":"Int. J. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.004_bib0105","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.CIR.38.5.846","article-title":"Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol","volume":"38","author":"Flamm","year":"1968","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2019.03.004_bib0110","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/hrt.44.5.488","article-title":"Effects of propranolol on myocardial oxygen consumption, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy","volume":"44","author":"Thompson","year":"1980","journal-title":"Br. Heart J."},{"issue":"6","key":"10.1016\/j.phrs.2019.03.004_bib0115","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/0002-9149(78)90687-2","article-title":"Long-term medical management of hypertrophic obstructive cardiomyopathy","volume":"42","author":"Frank","year":"1978","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.phrs.2019.03.004_bib0120","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/S0735-1097(99)00421-0","article-title":"A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment","volume":"34","author":"\u00d6stman-Smith","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.phrs.2019.03.004_bib0125","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/hrt.32.6.804","article-title":"Long-term propranolol therapy in muscular subaortic stenosis","volume":"32","author":"Adelman","year":"1970","journal-title":"Br. Heart J."},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2019.03.004_bib0130","first-page":"53","article-title":"Hypertrophic cardiomyopathy: a review","volume":"8","author":"Houston","year":"2015","journal-title":"Clin. Med. Insights Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.004_bib0135","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000175883","article-title":"Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy","volume":"82","author":"Tendera","year":"1993","journal-title":"Cardiology"},{"issue":"7","key":"10.1016\/j.phrs.2019.03.004_bib0140","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0735-1097(93)90386-F","article-title":"A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy","volume":"21","author":"Gilligan","year":"1993","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.004_bib0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/hrt.42.1.35","article-title":"Treatment of hypertrophic obstructive cardiomyopathy with verapamil","volume":"42","author":"Kaltenbach","year":"1979","journal-title":"Br. Heart J."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.004_bib0150","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.CIR.64.4.787","article-title":"Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy","volume":"64","author":"Bonow","year":"1981","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2019.03.004_bib0155","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1161\/01.CIR.79.5.1052","article-title":"Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy","volume":"79","author":"Udelson","year":"1989","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.phrs.2019.03.004_bib0160","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0002-9149(84)80142-3","article-title":"Improvement in left ventricular diastolic function during intravenous and oral diltiazem therapy in patients with hypertrophic cardiomyopathy: an echocardiographic study","volume":"54","author":"Suwa","year":"1984","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.004_bib0165","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0002-9149(96)00336-0","article-title":"Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy","volume":"78","author":"Betocchi","year":"1996","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.004_bib0170","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.65.3.499","article-title":"Modification of abnormal left ventricular diastolic properties by nifedipine in patients with hypertrophic cardiomyopathy","volume":"65","author":"Lorell","year":"1982","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.phrs.2019.03.004_bib0175","doi-asserted-by":"crossref","first-page":"J15","DOI":"10.1016\/0002-9149(89)91191-0","article-title":"New observations on the mechanisms of antiarrhythmic actions of disopyramide on cardiac membranes","volume":"64","author":"Hiraoka","year":"1989","journal-title":"Am. J. Cardiol."},{"issue":"12","key":"10.1016\/j.phrs.2019.03.004_bib0180","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/phar.1664","article-title":"Disopyramide for hypertrophic cardiomyopathy: a pragmatic reappraisal of an old drug","volume":"35","author":"Verlinden","year":"2015","journal-title":"Pharmacother.: J. Hum. Pharmacol. Drug Ther."},{"issue":"16","key":"10.1016\/j.phrs.2019.03.004_bib0185","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0002-9149(88)90553-X","article-title":"Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy","volume":"62","author":"Sherrid","year":"1988","journal-title":"Am. J. Cardiol."},{"issue":"8","key":"10.1016\/j.phrs.2019.03.004_bib0190","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.phrs.2019.03.004_bib0195","doi-asserted-by":"crossref","first-page":"e005152","DOI":"10.1161\/JAHA.116.005152","article-title":"Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients","volume":"6","author":"Adler","year":"2017","journal-title":"J. Am. Heart Assoc."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.004_bib0200","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s00380-014-0534-3","article-title":"Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide","volume":"30","author":"Haruki","year":"2015","journal-title":"Heart Vessels"},{"issue":"5","key":"10.1016\/j.phrs.2019.03.004_bib0205","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3904\/kjim.2014.29.5.571","article-title":"Adverse effects of long-term amiodarone therapy","volume":"29","author":"Park","year":"2014","journal-title":"Korean J. Intern. Med."},{"issue":"10092","key":"10.1016\/j.phrs.2019.03.004_bib0210","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0140-6736(16)31713-5","article-title":"Dilated cardiomyopathy","volume":"390","author":"Weintraub","year":"2017","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.phrs.2019.03.004_bib0215","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"K\u00f8ber","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.004_bib0220","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.hrthm.2017.12.018","article-title":"Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy","volume":"15","author":"Hyman","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.phrs.2019.03.004_bib0225","doi-asserted-by":"crossref","first-page":"f55","DOI":"10.1136\/bmj.f55","article-title":"Benefits of \u03b2 blockers in patients with heart failure and reduced ejection fraction: network meta-analysis","volume":"346","author":"Chatterjee","year":"2013","journal-title":"BMJ: Br. Med. J."},{"key":"10.1016\/j.phrs.2019.03.004_bib0230","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2261-13-52","article-title":"\u03b2-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials","volume":"13","author":"Al-Gobari","year":"2013","journal-title":"BMC Cardiovasc. Disord."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.004_bib0235","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1253\/jcj.64.87","article-title":"Effect of beta-blocker therapy on severe ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy","volume":"64","author":"Inoue","year":"2000","journal-title":"Jpn. Circ. J."},{"issue":"15","key":"10.1016\/j.phrs.2019.03.004_bib0240","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1053\/euhj.1999.1984","article-title":"Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study","volume":"21","author":"Iacono","year":"2000","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.004_bib0245","first-page":"535","article-title":"Early arrhythmic events in idiopathic dilated cardiomyopathy","volume":"2","author":"Losurdo","year":"2016","journal-title":"JACC: Clin. Electrophysiol."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.004_bib0250","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.295.2.165","volume":"295","author":"Connolly","year":"2006","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.phrs.2019.03.004_bib0255","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1540-8159.2007.00825.x","article-title":"Effect of dl-sotalol on mortality and recurrence of ventricular tachyarrhythmias: ischemic compared to nonischemic cardiomyopathy","volume":"30","author":"Furushima","year":"2007","journal-title":"Pacing Clin. Electrophysiol."},{"issue":"6","key":"10.1016\/j.phrs.2019.03.004_bib0260","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1161\/CIR.0000000000000426","article-title":"Drugs that may cause or exacerbate heart failure: a scientific statement from the american heart association","volume":"134","author":"Page","year":"2016","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.phrs.2019.03.004_bib0265","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0025-6196(12)65077-0","article-title":"New antiarrhythmic drugs: tocainide, Mexiletine, flecainide, encainide, and amiodarone","volume":"62","author":"Kreeger","year":"1987","journal-title":"Mayo Clin. Proc."},{"issue":"5, Part 2","key":"10.1016\/j.phrs.2019.03.004_bib0270","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/0002-8703(84)90175-3","article-title":"Pharmacology, electrophysiology, and pharmacokinetics of mexiletine","volume":"107","author":"Woosley","year":"1984","journal-title":"Am. Heart J."},{"issue":"5, Part 2","key":"10.1016\/j.phrs.2019.03.004_bib0275","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/0002-8703(84)90180-7","article-title":"Long-term mexiletine for ventricular arrhythmia","volume":"107","author":"Stein","year":"1984","journal-title":"Am. Heart J."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.004_bib0280","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/0002-9149(81)90191-0","article-title":"Mexiletine for ventricular arrhythmias","volume":"47","author":"Podrid","year":"1981","journal-title":"Am. J. Cardiol."},{"issue":"8","key":"10.1016\/j.phrs.2019.03.004_bib0285","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/0002-9149(83)90515-5","article-title":"Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation","volume":"52","author":"Morady","year":"1983","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.004_bib0290","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-8703(87)90711-3","article-title":"Ventricular arrhythmias in dilated cardiomyopathy: efficacy of amiodarone","volume":"113","author":"Neri","year":"1987","journal-title":"Am. Heart J."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.004_bib0295","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0735-1097(97)00220-9","article-title":"Adverse effects of low dose amiodarone: a meta-analysis","volume":"30","author":"Vorperian","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.004_bib0300","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199507133330201","article-title":"Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia","volume":"333","author":"Singh","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.004_bib0305","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10557-015-6583-8","article-title":"Pharmacotherapy and other therapeutic modalities for managing Arrhythmogenic Right Ventricular Cardiomyopathy","volume":"29","author":"Rigato","year":"2015","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"15","key":"10.1016\/j.phrs.2019.03.004_bib0310","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMc1701400","article-title":"Arrhythmogenic right ventricular cardiomyopathy","volume":"376","author":"Corrado","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.phrs.2019.03.004_bib0315","doi-asserted-by":"crossref","first-page":"959","DOI":"10.4330\/wjc.v6.i9.959","article-title":"Ventricular tachycardia mapping and ablation in arrhythmogenic right ventricular cardiomyopathy\/dysplasia: lessons learned","volume":"6","author":"Tschabrunn","year":"2014","journal-title":"World J. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.004_bib0320","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s10897-012-9497-7","article-title":"Arrhythmogenic right ventricular dysplasia\/cardiomyopathy (ARVD\/C): a review of molecular and clinical literature","volume":"21","author":"Murray","year":"2012","journal-title":"J. Genet. Couns."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.004_bib0325","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/01.CIR.86.1.29","article-title":"Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia","volume":"86","author":"Wichter","year":"1992","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.phrs.2019.03.004_bib0330","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jacc.2009.04.052","article-title":"Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC registry","volume":"54","author":"Marcus","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"25","key":"10.1016\/j.phrs.2019.03.004_bib0335","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1161\/01.CIR.0000103130.33451.D2","article-title":"Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy\/dysplasia","volume":"108","author":"Corrado","year":"2003","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2019.03.004_bib0340","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.017944","article-title":"Treatment of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: an international task force consensus statement","volume":"132","author":"Corrado","year":"2015","journal-title":"Circulation"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819302865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819302865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:56:04Z","timestamp":1760910964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819302865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":68,"alternative-id":["S1043661819302865"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.03.004","relation":{},"ISSN":["1043-6618"],"issn-type":[{"type":"print","value":"1043-6618"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-arrhythmic therapy in patients with non-ischemic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}